Lexeo Therapeutics, Inc. (LXEO) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Lexeo Therapeutics reported revenue of $0. Net income was -$100.0M, or -$1.86 per diluted share. Operating activities generated -$98.6M of cash, leaving -$99.0M of free cash flow. At fiscal year end, Lexeo Therapeutics held $268.7M in total assets against $22.0M in total liabilities, including $63.0M of cash and equivalents.
Open the full interactive Lexeo Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Lexeo Therapeutics Key Stats
| Share Price | $2.74 |
|---|---|
| Market Cap | $234.6M |
| 52-Week Range | $2.74 – $10.63 |
| Shares Outstanding | 85.6 million (basic, 2026 Q2) |
Lexeo Therapeutics Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Income | -$68.5M | -$105.8M | -$109.3M |
| Pre-Tax Income | -$66.4M | -$98.3M | -$99.7M |
| Income Tax | — | — | $0 |
| Net Income | -$66.4M | -$98.3M | -$100.0M |
| Diluted EPS | -$12.40 | -$3.09 | -$1.86 |
Lexeo Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$20.3M | -$20.9M | -$20.2M | -$25.9M |
| Diluted EPS | -$0.33 | -$0.39 | -$0.25 | -$0.30 |
Lexeo Therapeutics Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $121.5M | $35.0M | $63.0M |
| Current Assets | $124.3M | $126.1M | $188.4M |
| Total Assets | $139.8M | $146.9M | $268.7M |
| Current Liabilities | $17.2M | $22.8M | $16.8M |
| Total Liabilities | $26.3M | $30.1M | $22.0M |
| Shareholders' Equity | $113.5M | $116.8M | $246.7M |
Lexeo Therapeutics Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$59.5M | -$81.2M | -$98.6M |
| Cash From Investing | -$165,000 | -$94.1M | -$90.3M |
| Cash From Financing | $103.8M | $88.8M | $216.8M |
| Free Cash Flow | -$59.6M | -$81.6M | -$99.0M |
Figures from Lexeo Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lexeo Therapeutics financials page for every line item.
Lexeo Therapeutics Company Profile
| Ticker | LXEO |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | New York, New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001907108 |
Frequently Asked Questions
What was Lexeo Therapeutics' revenue in fiscal 2025?
Lexeo Therapeutics (LXEO) reported revenue of $0 for fiscal 2025.
What is Lexeo Therapeutics' annual revenue history?
Lexeo Therapeutics' annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was Lexeo Therapeutics' net income in fiscal 2025?
Lexeo Therapeutics reported net income of -$100.0M for fiscal 2025.
What was Lexeo Therapeutics' earnings per share (EPS) in fiscal 2025?
Lexeo Therapeutics' diluted EPS was -$1.86 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Lexeo Therapeutics generate in fiscal 2025?
Lexeo Therapeutics generated -$99.0M of free cash flow in fiscal 2025.
What was Lexeo Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Lexeo Therapeutics reported revenue of $0.
How many shares of Lexeo Therapeutics are outstanding?
Lexeo Therapeutics reported a weighted average of 85.6 million basic shares outstanding in 2026 Q2.
What is Lexeo Therapeutics' market cap?
Based on its latest closing price, Lexeo Therapeutics (LXEO) has a market capitalization of about $234.6M.
When does Lexeo Therapeutics' fiscal year end?
Lexeo Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Lexeo Therapeutics headquartered?
Lexeo Therapeutics lists its business address in New York, New York in its SEC filings.
Lexeo Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →